Surh C D, Danner D J, Ahmed A, Coppel R L, Mackay I R, Dickson E R, Gershwin M E
Department of Internal Medicine, University of California, Davis 95616.
Hepatology. 1989 Jan;9(1):63-8. doi: 10.1002/hep.1840090110.
Antimitochondrial autoantibodies recognizing 68 to 74 and 50 to 52 kD inner membrane mitochondrial antigens are characteristically present in sera of patients with primary biliary cirrhosis. The biochemical identification of the antigens, however, has remained elusive. We report herein that the 52 kD antigen is the dihydrolipoamide acyltransferase of the branched-chain alpha-keto acid dehydrogenase complex. This was demonstrated by three experiments through the use of recombinant fusion protein expressed in Escherichia coli from a cDNA insert encoding the human autoantigen. First, 33 of 37 primary biliary cirrhosis patients exhibiting reactivity toward the 50 to 52 kD mitochondrial antigen by immunoblotting also showed reactivity toward the recombinant fusion protein. Second, absorption of primary biliary cirrhosis sera with recombinant fusion protein, but not with an irrelevant recombinant clone, the F-specific rat liver antigen, was effective in absorbing out reactivity against the 50 to 52 kD mitochondrial antigen but not the 68 to 74 kD antigen. Third, complete removal of reactivity toward all four different isoelectric point polypeptides at 50 to 52 kD was observed in two-dimensional gel analysis. Furthermore, primary biliary cirrhosis sera were analyzed with mitochondria from three sources, rat liver, human placenta and bovine heart, in order to compare reactivity patterns and to determine precisely the comparative molecular weights of the autoantigens in the three species. The availability of recombinant autoantigens will provide improved diagnostic tests and, more importantly, will allow definite issues in primary biliary cirrhosis to be studied, including identification of immunodominant epitopes, the significance of autoantigen recognition and the establishment of autoreactive T cell clones.
识别68至74kD和50至52kD线粒体内膜抗原的抗线粒体自身抗体典型地存在于原发性胆汁性肝硬化患者的血清中。然而,这些抗原的生化鉴定仍然难以捉摸。我们在此报告,52kD抗原是支链α-酮酸脱氢酶复合体的二氢硫辛酰胺酰基转移酶。通过三项实验证明了这一点,这三项实验使用了从编码人类自身抗原的cDNA插入片段在大肠杆菌中表达的重组融合蛋白。首先,37例通过免疫印迹对50至52kD线粒体抗原呈反应性的原发性胆汁性肝硬化患者中,有33例对重组融合蛋白也呈反应性。其次,用重组融合蛋白而非无关的重组克隆F特异性大鼠肝抗原吸收原发性胆汁性肝硬化血清,可有效吸收针对50至52kD线粒体抗原的反应性,但不能吸收针对68至74kD抗原的反应性。第三,在二维凝胶分析中观察到对50至52kD的所有四种不同等电点多肽的反应性完全消除。此外,用来自大鼠肝脏、人胎盘和牛心脏的三种来源的线粒体分析原发性胆汁性肝硬化血清,以比较反应模式并精确确定三种物种中自身抗原的相对分子量。重组自身抗原的可用性将提供改进的诊断测试,更重要的是,将允许研究原发性胆汁性肝硬化中的明确问题,包括免疫显性表位的鉴定、自身抗原识别的意义以及自身反应性T细胞克隆的建立。